Neil supports the Basel Life Sciences Accelerator program of BaselArea.swiss as Director Strategy.
Previously, Neil Goldsmith was Co-founder, CEO and board member of Evolva SA, listed on SIX.
Co-founder of Topotarget A/S, listed on the CSE. Co-founder of Personal Chemistry AB, now Biotage AB, listed on NASDAQ Stockholm and various other life science ventures.
Board member of Unibio and Double Bioventures
Stephan is Director Business Development & Operations and Senior Project Manager Biotech at BaselArea.swiss.
Research in the area of RNAi/Epigenetics and Cardiovascular Diseases at FMI/Novartis and Roche
PhD from Uni Basel/FMI/Novartis. Master´s and Bachelor´s degree in Biochemistry and Molecular Biology, ETH Zürich
Leonildo is Manager, Innovation & Sourcing.
Research at the Biozentrum of the University of Basel. Incl. collaborations with GE Healthcare, Hoffmann-La Roche.
PhD in Structural Biology. Master’s and Bachelor’s degree in Biochemistry, food chemistry and molecular biotechnology at the University of Aveiro
Isabelle supports BaseLaunch as Marketing Manager and in addition Project Manager Marketing at BaselArea.swiss.
Director Communications at Evolva and various Marketing and Sales roles in market leading companies
eMBA in Cross-cultural Leadership from FHNW and EBS, Heriot-Watt University
Besides heading the operations area of BaseLaunch, Cornelia is in charge of stakeholder management and serves as Executive Assistant to the Managing Director of BaselArea.swiss.
Administration and Assistant to the Management Board at i-net innovation networks. Other roles at the Little Gym Europe and FIPRA in Brussels
Programmer and analyst as a database administrator at Swisscom
Dr. Michael Hübner is New Venture Lead at Johnson & Johnson Innovation, where he is responsible for establishing partnerships with life science companies in Switzerland and in the EMEA region.
Prior to joining Johnson & Johnson, Michael was Business Development and Licensing Manager at F.Hoffmann-La Roche where he led the scientific assessment and Due Diligence of preclinical and clinical stage external programs, and he scouted for innovative research at scientific and partnering conferences globally. During his 5 years at Roche, he closed licensing and acquisition deals totaling over 1bn Euros.
Before joining Roche, Michael was a scientist for 10 years at Cold Spring Harbor Laboratory (USA), where he worked as an EMBO fellow and DAAD scholar. Michael earned a PhD summa cum laude from the European Molecular Biology Laboratory (EMBL), and a Diploma in biochemistry from Tübingen University (Germany).
Sascha Bucher is the Head of Global Transactions at Roivant based in Basel. Prior to joining Roivant, Sascha worked for Roche in numerous Business and Corporate Development functions including as Deputy Head of Global M&A where he was involved in 100+ transactions and negotiated and closed over 35 global deals. Prior to Roche, Sascha was a banker at UBS. He holds an MBA in Finance and Economics from the University of Basel, and is both a Harvard Business School GMP alumnus and a Certified European Financial Analyst and Asset Manager.
Dr. Jakob Busch-Petersen is an Intrapreneur in Roche’s External Innovation Group (Therapeutic modalities) where he is responsible for scouting, developing and executing novel early stage therapeutic and technology programs with external partners. Before joining Roche in 2015, he worked in a similar capacity in GlaxoSmithKline’s Discovery Partnerships with Academia. Jakob started his industrial career in 2000 as a medicinal chemist at SmithKline-Beecham. His track record includes the marketed muscarinic antagonist umeclidinium bromide (Anoro/Incruise) as well as the late stage CXCR2 antagonist danirixin for which he was the project leader and sole inventor. Jakob holds a Ph.D in organic chemistry from the University of Hawaii and conducted post-doctoral research with Nobel laureate with E. J. Corey at Harvard University.
Trudi Haemmerli started her career at the Paul Scherrer Institute and then joined Ciba-Geigy. She had a key role during the merger in 1996 to create Novartis and continued her career with increasing responsibility in Regulatory Affairs, and leading the Global Regulatory CMC department for over 5 years. She then moved to the US to run Global Research Operations before returning to Basel in 2010 to help restructure Novartis’ Compliance organisation and policies. In April 2014, she left Novartis to become CEO and Director at PerioC Ltd., a Life Sciences start-up. She is also Managing Director of TruStep Consulting GmbH. She joined as a new member of the Swiss Commission for Technology and Innovation for Startups and Entrepreneurship (CTI) in January 2016 and has recently been appointed to the Board of Directors for the new Innosuisse that replaces CTI from January 2018. She is also an active Business Angel investor.
Trudi Haemmerli studied Chemistry in the UK, completed the ECPM Certification at the University of Basel in 2007 and graduated with the St. Gallen MBA in 2013.
Dr. Florian Muellershausen is a Principal at NVF in Basel, Switzerland. Prior to joining Novartis Venture Fund, he worked as a Scientific Manager for the R&D Committee of the Novartis Board of Directors and, before that held various scientific and drug discovery roles at the Novartis Institute of Biomedical Research (NIBR) including as Laboratory Head in target discovery and in early clinical research as Translational Medicine Expert, Autoimmunity. Florian received his MSc degree in Biochemistry from Free University Berlin and his PhD degree with great distinction in Biochemistry from Ruhr University Bochum and completed his post-doctoral training at NIBR in Switzerland.
Dr. Alex Mayweg is Partner at Versant Venture’s Basel office in Switzerland.
Alex joined Versant in 2016 from F. Hoffmann La Roche where he served as global head of medicinal chemistry. He previously held various other appointments and positions at Roche’s Basel and Shanghai site, having joined Roche in 2003. Prior to Roche, Alex earned a Ph.D. in organic chemistry at Oxford University, followed by post doctorate training at Stanford University. His undergraduate degree was in chemistry from the Imperial College of Science and Technology in London.
Ulrich Zügel is the Emerging Science & Innovation Lead - Inflammation & Immunology Europe at Pfizer. He is responsible for scouting of preclinical partnering opportunities in Europe and establishing new collaborations across all therapeutic areas. Ulrich has more than 20 years of international experience in Pharma R&D. Prior to joining Pfizer, Ulrich held several senior management positions at siRNA therapeutics, USA and Silence Therapeutics GmbH, Germany. Before that he had different management positions at BAYER AG and Schering AG. During his career he successfully delivered numerous candidates to development in different disease areas. His academic career included postdoctoral work at the La Jolla Institute for Allergy and Immunology in San Diego, USA and the University of Ulm, Germany. He is author of >50 scientific publications.
Our advisors have deep hands-on knowledge and expertise in all relevant aspects of drug development and entrepreneurship. We connect entrepreneurs with advisors that have the most relevant experience in a particular therapeutic or functional area and that can generate an immediate impact.
Carlo Bertozzi is the Director of Operations at Heptares Therapeutics Zurich AG in Schlieren Switzerland. He holds a Diploma in Biophysics and Physical-Chemistry from ETHZ and a PhD in Biochemistry from the University of Zurich.
During his PhD Carlo Bertozzi co-founded a boutique chocolate consulting company, with the focus on market enabling for Italian companies. In 2014, he stepped down from his position as a partner, yet remain as a supervisor to the board and management, since he established G7 Therapeutics in 2014. He served the company as CEO and was a member of the Board until it was sold in December 2016 to Heptares Therapeutics Ltd. After the M&A he remained the CEO and a member of the Board of G7 Therapeutics, which was subsequently renamed to Heptares Therapeutics Zurich AG until November 2017. To align with the company structure and responsibilities, his job description changed since November to Director of Operations.
Juergen Heitmann, a Biologist by training served more than 20 years in various positions in the healthcare industry with significant career steps at McKinsey & Co., Novartis and Nycomed/Takeda. His main focus in on business development and corporate strategy. Since 2014 he operates as an independent Business Development Consultant for various clients.
Paul N. Jenner qualified in medicine from St Mary’s Hospital, University of London and, after spending 8 years in clinical medicine, has over 30 years’ experience in the pharmaceutical industry. He is a Member of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians and a Member of the European College of Neuropsychopharmacology.
Dr Jenner has held a variety of roles in clinical development, medical affairs and marketing in the neuroscience area. He was formerly Vice President, Commercial Development, Psychiatry Clinical Development & Product Strategy, GlaxoSmithKline and, from 2002 to 2016, was Global Head, New Products, Neuroscience, Novartis AG based in Basel, Switzerland. He has extensive worldwide strategic marketing experience in USA, major European markets, Japan and key international markets with responsibilities for products in depression/anxiety, psychosis, ADHD, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, epilepsy, stroke, neuropathic pain and migraine.
Dr. Karin Jorga is the owner of KarinJorga Life Science Consulting GmbH based in Basel. She offers drug development consulting to Biotech and Pharma companies and supports investors with Due Diligence assessments. Her focus includes early drug development and in particular the transition of innovative drug candidates from pre-clinical assessments to entry-into-human and clinical proof-of concept. Before opening her own business, Karin worked for F. Hoffmann La Roche at the Basel and several US sites including Genentech in South San Francisco. She held various positions in Pharma R&D including Global Head Clinical Pharmacology, Global Head Modeling and Simulation and Global Head Biomarker Science and Technology. Prior to joining Roche in 1991, Karin earned a Ph.D. in Pharmaceutical Chemistry at the Christian-Albrechts University in Kiel, Germany, followed by post doctorate training at the University of Lexington in Kentucky, US.
Dr. Martina Kaufmann has roughly 20 years industry experience in the field of personalized medicine - from biomarker validation, companion diagnostics development to implementation of such products in the market.
She served in various roles of increasing responsibility in business and development functions in small biotech / diagnostic companies as well as in global pharmaceutical & diagnostics corporations (Hoffmann-La Roche AG, Novartis Pharma AG, Novartis Molecular Diagnostics).
Since April 2012 she is offering her comprehensive and longtime experience as a consultant to an international clientele in both pharma and diagnostics industry
Her services range from strategic concept development to project specific consulting for CDx development under consideration of strategic, scientific, regulatory, operational and commercial aspects.
Helmut is a serial entrepreneur and successful Business / Corporate Development Executive in Biotech. He is co-founder of two Biotech companies which both developed to IPO and beyond (Disovery Partners, IPO at NasdaQ in 2000; Santhera, IPO at SIX in 2006), is cofounder / Board member of T3 Pharma, and advisor to other Biotech companies. He has a strong track record of successful negotiation and deal making with extensive experience in technology, development stage and product focused transactions across therapeutic areas world-wide. These deals included in- and outlicensing tranactions, non-dilutive fundings, MBOs and several M&As. Prior to that he held research management positions at Ciba-Geigy, now Novartis. Helmut studied biology, philosophy and business administration and completed his PhD in biochemistry in 1988 at the University Münster, Germany.
Results-driven executive with a PhD in biochemistry and 21 years experience driving the development, regulatory approval, and commercialization of new drugs and medical advancements. Proven leader of global business operations with development experience spanning such corporations as Novartis and Baxter, as well as a co-founder of VC-funded biotech start-ups. Highly skilled at translating innovative concepts into marketable products with a firm dedication to the overarching goal of developing novel, safe treatments that serve patients in need.
Matthias Machacek is Managing Director at LYO-X, a service and consulting company for Systems Pharmacology and the PK/PD of biologics and novel therapeutic formats. Previously he was head of the Engineering Cluster at Novartis managing the in silico modelling support for the biologics in the preclinical and translational portfolio. Matthias has a Masters Degree that he completed at the University of Tokyo in Fluid Dynamics and he holds a PhD in Mechanical Engineering from the ETH Zurich. He got his Life Science exposure during his postdoctoral research at the Scripps Research Institute in San Diego.
Kevin McAllister is the Managing Director of Neurenable GmbH, a company enabling Neuroscience research and development by offering advisory, project management and due diligence services to entrepreneurs, venture capital, pharma and non-profit organisations. Prior to this he was Executive Director in the Neuroscience Disease Area, Novartis Institutes for Biomedical Research, and Principal Medical Scientific Expert in the Novartis Neuroscience Development Franchise. Kevin holds a PhD from the University of Wales, UK, and an MBA from the International Institute for Management Development, Lausanne, Switzerland.
Matthias Staufenbiel currently is Research Consultant at the Hertie Institute for Clinical Brain Research, University of Tübingen. Previously he had leading positions in Novartis and Sandoz Preclinical Neuroscience Research focusing on Neurodegeneration and in particular Alzheimer's Disease. Before he hold an independent research position at the Max-Planck-Institute for Cell Biology in Ladenburg and a postdoc position in cell biology at the California Institute of Technology, Pasadena. Matthias has studied biology at the University of Konstanz and received his Ph.D. from the Max-Planck-Institute for Biophysical Chemistry in Göttingen and the University of Ulm. He is co-author of more than 200 scientific publications.